Investigating how p53 mutations contribute to early ovarian cancer development
Targeting p53 conformational defects to arrest carcinogenesis
This study is looking at how changes in a gene called p53 might help us spot early signs of ovarian cancer, especially in women who have a condition called tubal intraepithelial carcinoma, so we can find better ways to detect and treat the disease sooner.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10663264 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of p53 mutations in the early stages of ovarian cancer, particularly in tubal intraepithelial carcinoma (TIC), which is a precursor to high-grade serous carcinoma. The study aims to analyze clinical samples to determine if the aggregation of mutant p53 proteins can be identified in pre-cancerous tissues. By examining these mutations, researchers hope to develop methods for early detection and potential therapeutic interventions for ovarian cancer. The approach involves analyzing archival ovarian cancer specimens to identify specific molecular events associated with cancer progression.
Who could benefit from this research
Good fit: Ideal candidates for this research include women with a family history of ovarian cancer or those diagnosed with pre-malignant lesions such as TIC.
Not a fit: Patients with advanced ovarian cancer or those without any genetic predisposition to ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection and prevention strategies for ovarian cancer, improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in targeting p53 mutations for cancer treatment, indicating potential success for this approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Soragni, Alice — University of California Los Angeles
- Study coordinator: Soragni, Alice
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.